Ritchie, Jennifer M.Greenwich, Jennifer L.Davis, Brigid M.Bronson, Roderick T.Gebhart, DanaWilliams, Steven R.Martin, DavidScholl, DeanWaldor, Matthew K.2019-10-052011Ritchie, Jennifer M., Jennifer L. Greenwich, Brigid M. Davis, Roderick T. Bronson, Dana Gebhart, Steven R. Williams, David Martin, Dean Scholl, and Matthew K. Waldor. 2011. “An Escherichia Coli O157-Specific Engineered Pyocin Prevents and Ameliorates Infection by E. Coli O157:H7 in an Animal Model of Diarrheal Disease.” Antimicrobial Agents and Chemotherapy 55 (12): 5469–74. https://doi.org/10.1128/aac.05031-11.0066-48041098-6596http://nrs.harvard.edu/urn-3:HUL.InstRepos:41483559AvR2-V10.3 is an engineered R-type pyocin that specifically kills Escherichia coli O157, an enteric pathogen that is a major cause of food-borne diarrheal disease. New therapeutics to counteract E. coli O157 are needed, as currently available antibiotics can exacerbate the consequences of infection. We show here that orogastric administration of AvR2-V10.3 can prevent or ameliorate E. coli O157:H7-induced diarrhea and intestinal inflammation in an infant rabbit model of infection when the compound is administered either in a postexposure prophylactic regimen or after the onset of symptoms. Notably, administration of AvR2-V10.3 also reduces bacterial carriage and fecal shedding of this pathogen. Our findings support the further development of pathogen-specific R-type pyocins as a way to treat enteric infections.en-USJournal Article2019-10-0510.1128/AAC.05031-11